Zymeworks Inc.

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.3 USD -1.62% Intraday chart for Zymeworks Inc. -4.19% -0.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024 CI
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting CI
Zymeworks Inc. Appoints Scott Platshon as Director CI
Transcript : Zymeworks Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-22-2024 08:00 AM
Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors CI
Transcript : Zymeworks Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM
Zymeworks Insider Sold Shares Worth $257,845, According to a Recent SEC Filing MT
Zymeworks Appoints Jeffrey Smith as Chief Medical Officer; Cash Runway Extended MT
Zymeworks Inc Announces Additional Leadership Appointments CI
Zymeworks Reports $50 Million Private Placement to EcoR1 Capital MT
Zymeworks Inc. announced that it expects to receive $49.999993 million in funding from EcoR1 Capital, LLC CI
Zymeworks Inc.(NasdaqGS:ZYME) added to NASDAQ Biotechnology Index CI
Zymeworks Expects to Be Added to Nasdaq Biotech Index MT
Zymeworks Inc. Announces Changes to its Board CI
Transcript : Zymeworks Inc., Q3 2023 Earnings Call, Nov 07, 2023
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Zymeworks Inc Announces Resignation of Lota Zoth as Member of the Board of Directors CI
Transcript : Zymeworks Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM
Transcript : Zymeworks Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 10:30 AM
Zymeworks Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Zymeworks Inc.
More charts
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas with an emphasis on developing ADC and multi-specific antibody therapeutics (MSAT) candidates. Its pipeline of preclinical product candidates includes two lead programs, ZW191 and ZW17.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.3 USD
Average target price
14.17 USD
Spread / Average Target
+37.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Zymeworks Inc. - Nasdaq
  4. News Zymeworks Inc.
  5. Wells Fargo Adjusts Zymeworks' Price Target to $45 From $56, Reiterates Overweight Rating